Select year
Often considered as our “second brain”, the human gut and its resident microbiota play a crucial bidirectional role communicating the brain (central nervous system) with the gut (enteric nervous system), in what is called the microbiota-gut-brain axis. Researchers of University of Gothenburg and BioGaia AB (NASDAQ: BIOG) have identified that specific bacteria present in the […]
THIRD QUARTER 2025 Net sales amounted to SEK 326.6 million (304.0), an increase of SEK 22.7 million, or an increase of 7% (excluding foreign exchange effects an increase of 14%). Net sales in the Pediatrics segment amounted to SEK 242.6 million (225.8), an increase of 7% (excluding foreign exchange effects an increase of 14%). Net […]
We are proud to announce that the scientific rationale and identification of our newly patented strain, Limosilactobacillus reuteri BG-R46®, has been published in the prestigious journal, Beneficial Microbes. This next-generation strain will be featured in our upcoming baby drops product. Developed by BioGaia AB (NASDAQ: BIOG) and a research team at the Swedish University of […]
BioGaia's (NASDAQ: BIOG) financial report for the third quarter of 2025 will be published at approximately 8:00 AM CEST on October 22, 2025. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website. CEO Theresa […]
We are thrilled to launch BioGaia Prodentis® FRESH BREATH lozenges, a microbiome-friendly dental probiotic with zinc that both supports healthy teeth and gums and promotes instant and long-lasting fresh breath. This innovation expands BioGaia’s specialized oral care portfolio of products, adding yet another probiotic format that is the world’s most researched for oral health. BioGaia […]
BioGaia AB (NASDAQ: BIOG) establishes its own distribution in Germany and Austria through a newly formed subsidiary in Germany which will distribute and market BioGaia’s products in both Germany and Austria under the company and brand name “BiGaia” (due to current market reasons the company and brand name has been BiGaia and not BioGaia). This […]
In a recent study, published in the European Journal of Pediatrics, BioGaia´s patented bacteria strain, Limosilactobacillus reuteri DSM 17938, was shown to prevent antibiotic-associated diarrhea (AAD) in children. The prospective, multi-center, randomized, placebo-controlled clinical trial, known as the PEARL Study, investigated the effect of L. reuteri DSM 17938 in children aged between 6 months and […]
Mauricio Graber, newly elected chairman of the board has entered into an agreement to purchase 735,754 class B shares from Anatom Holding, BioGaia’s anchor shareholder. The significant investment underlines Mauricio Graber’s commitment to actively supporting the company’s future development and its management team and creates a strong alignment of interests with all stakeholders. Following settlement […]
Dear Shareholders, Partners, and Friends of BioGaia, Since founding BioGaia with Jan Annwall in 1990, I have had the privilege of leading this company in various capacities over the decades – sometimes from the front as CEO or Chairman, sometimes from behind the scenes – but always with the same unwavering passion for our mission: […]
Be the first to know all about the latest news from BioGaia.
Subscribe
